司美格鲁肽口服制剂治疗2型糖尿病临床研究进展  

Clinical Research Progress of Smeglutide Oral Preparation in the Treatment of Type 2 Diabetes Mellitus

作　　者：张奎传 李妍[2] ZHANG Kuichuan;LI Yan(Hekou Community Health Service Center of Hekou District in Dongying City,Dongying,Shandong,China 257200;The First Affiliated Hospital of Shandong First Medical University·Qianfoshan Hospital,Jinan,Shandong,China 250014)

机构地区：[1]山东省东营市河口区河口社区卫生服务中心,山东东营257200 [2]山东第一医科大学第一附属医院·山东省千佛山医院,山东济南250014

出　　处：《中国药业》2024年第21期I0001-I0004,共4页China Pharmaceuticals

摘　　要：目的为司美格鲁肽口服制剂治疗2型糖尿病(T2DM)的临床应用提供参考。方法采用计算机检索PubMed、Medline、EMBase、TheCochraneLibrary、中国生物医学文献、中国知网、万方、维普等数据库中司美格鲁肽口服制剂治疗T2DM的相关文献,检索时限为自建库起至2023年4月,总结司美格鲁肽口服制剂的药代动力学特点及其治疗T2DM的有效性与安全性。结果与结论司美格鲁肽口服制剂单用或联用其他降血糖药物治疗T2DM,均能良好地控制血糖、减轻体质量,且耐受性良好,安全性与胰高血糖素样肽-1受体激动剂注射剂一致。Objective To provide a reference for the clinical application of smeglutide oral preparation in the treatment of type 2 diabetes mellitus(T2DM).Methods The literature related semaglutide oral preparations in the treatment of T2DM in the PubMed Medline,EMBase,The Cochrane Library,CBMdisc,CNKI,WanFang,and VIP databases were searched from the inception of the database to April 2023.The pharmacokinetic characteristics of semaglutide oral preparations and their effectiveness and safety in the treatment of T2DM were summarized.Results and Conclusion The semaglutide oral preparations,when used alone or in combination with other hypoglycemic drugs,can effectively control blood sugar and reduce body weight in the treatment of T2DM,with good tolerability and safety consistent with glucagon like peptide-1 receptor agonist(GLP-1RA)injection.

关 键 词：司美格鲁肽 口服制剂 2型糖尿病 胰高血糖素样肽-1受体激动剂 进展 

分 类 号：R977.12[医药卫生—药品]